Although not used in the clinic to date, HSD11B1 inhibitors have been widely developed in the framework of metabolic diseases.34 Our study provides a rationale to further investigate whether these inhibitors could be repurposed for the treatment of cancer by boosting antitumor immunity. Here, HSD11B1 is linked to metabolic disease.